Aelix commences enrolment in Phase I trial for HIV vaccine

Spanish biotechnology firm Aelix Therapeutics has commenced patient enrolment in a Phase I clinical trial (AELIX-002) of HTI vaccine to treat patients infected with HIV.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news